If you have been reading about anti-doping and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-30. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
==== Cells ==== Sponges have around 6 different types of cells that can perform different functions. Sponges are a good model for studying the origin of multicellularity because the cells are capable of communicating with one another and re-aggregating. In an experiment conducted by Henry Van Peters Wilson in 1910, it was found that cells from dissociated sponges could send out signals and recognize each other to form a new individual. This suggests that the cells that compose sponges are capable of independent living, however once multicellularity was possible then aggregating together to form one organism was a more efficient way of living.
distal Wallerian degeneration partial or complete connective tissue lesion severe sensory-motor problems and autonomic function defect nerve conduction distal to the site of injury absent (3 to 4 days after lesion) no distal conduction (EMG and NCV (nerve conduction velocity) surgical intervention is necessary to restore function due to the full disruption of the nerve and connective tissue structures.
== Treatment == The main focus of treatment for AGAT deficiency is supplementation of creatine, with the goal of replenishing cerebral creatine to normal levels. This is done with oral creatine supplementation. Treatment is most effective if it is started early in life, before symptoms are apparent. Treatment in affected individuals does not reverse intellectual disability or improve cognitive function. For treatment at any age, even if intellectual disability was present, all individuals showed improvement in muscle weakness. In an asymptomatic sibling, who was started on treatment due to the earlier diagnosis of an affected sibling, early intervention with creatine supplementation resulted in improved outcomes when compared to their untreated siblings at the same age. In addition to clinical findings, the effectiveness of treatment can be monitored by following creatine levels in blood and urine as well as the creatine signal by MRS. As creatine is rapidly converted and excreted as creatinine, treatment must be life long to continue to benefit the patient. Treatment during the early years of brain development is most important for preserving brain function.
== The document == The document was presented to the British Museum in 1924 by Walter Rothschild; today it is held in the British Library, which separated from the British Museum in 1973, as Additional Manuscripts number 41178. From October 1987 to May 1988 it was lent outside the UK for display in Israel's Knesset.
Sources: en.wikipedia.org
However, most colonies in Africa, even those rich in natural resources, experienced difficulty in achieving similar rates of development due to a shortage of technical and managerial skills. Small, rotating cadres of colonial civil servants who possessed little incentive to invest their skills in the local economy were insufficient to compensate for this disadvantage. Southern Rhodesia had negated the issue by importing a skilled workforce directly from abroad in the form of its disproportionately large European immigrant and expatriate population. For example, in 1951 over 90% of white Southern Rhodesians were engaged in what the British government classified as "skilled occupations", or professional and technical trades. This made it possible to establish a diversified economy with a strong manufacturing sector and iron and steel industries, and circumvent the normal British protectionist policy of supporting domestic industry in the metropole while discouraging industry in the colonies abroad. As the white population increased, so did capital imports, especially in the wake of the Second World War. This trend, too, stood in sharp contrast to most other colonial territories, which suffered a major capital deficit due to revenues simply being repatriated to the metropole, leaving little capital to be invested locally. The considerable investment made by white Rhodesians in the economy financed the development of Southern Rhodesia's export industries as well as the infrastructure necessary to integrate it further with international markets.
While iron is the most abundant element on Earth, most of this iron is concentrated in the inner and outer cores. The fraction of iron that is in Earth's crust only amounts to about 5% of the overall mass of the crust and is thus only the fourth most abundant element in that layer (after oxygen, silicon, and aluminium). Most of the iron in the crust is combined with various other elements to form many iron minerals. An important class is the iron oxide minerals such as hematite (Fe2O3), magnetite (Fe3O4), and siderite (FeCO3), which are the major ores of iron. Many igneous rocks also contain the sulfide minerals pyrrhotite and pentlandite. During weathering, iron tends to leach from sulfide deposits as the sulfate and from silicate deposits as the bicarbonate. Both of these are oxidized in aqueous solution and precipitate in even mildly elevated pH as iron(III) oxide.
Congenital muscular dystrophies are autosomal recessively-inherited muscle diseases. They are a group of heterogeneous disorders characterized by muscle weakness which is present at birth and the different changes on muscle biopsy that ranges from myopathic to overtly dystrophic due to the age at which the biopsy takes place.
National Security Agency monitored a telephone conversation between Noriega and Luis Córdoba, the military commander in Chiriquí province where Spadafora was arrested. During the conversation Córdoba told Noriega, "We have the rabid dog." Noriega responded, "And what does one do with a dog that has rabies?" Spadafora's murder badly damaged Noriega's image, both within and outside Panama, and created a crisis for the Panamanian regime. Barletta, who was in New York City when Spadafora was murdered in September 1985, announced his intention to appoint an independent commission to investigate the murder. Upon his return to Panama, however, he was forced to resign by the PDF and was replaced by Vice President Eric Arturo Delvalle. Barletta was highly regarded in the Reagan administration, and his removal brought a downturn in the relations between the U.S. and Noriega. After Spadafora's murder the U.S. began to view Noriega as a liability rather than an asset, despite his ongoing support for U.S. interventions elsewhere. The U.S. response included reducing economic assistance and pressuring Panama to reform its banking secrecy laws, crack down on narcotics trafficking, investigate the murder of Spadafora, and reduce the PDF's role in the government. The response to Spadafora's murder created divisions within the PRD, and further damaged the credibility of the government-controlled news media.
== Receptor == The receptor for CNMa (CG33696) is a G protein-coupled receptor. Phylogenetic analysis identified two separate clades of CNMaRs in arthropod species, but many taxa retain only one. Existence of two paralogous CNMaRs suggests that CNMaR has additional ligands in some insect species. This assumption is also supported by absence of the gene for CNMa in the genome of Lepidopteran species (such as Bombyx mori and Danaus plexippus) that retain the CNMaR.
Sources: en.wikipedia.org
== Side effects == There had been concern that lorcaserin could cause cardiac valvulopathy based upon the reports of subjects taking the drug in Phase 2 trials. However, a 2016 Phase 3 clinical trial found no statistically significant differences in valvulopathy rates compared to control, being 2.4% for the drug subjects and 2.0% for controls, and concluded that the drug was safe for the target population although more long-term data was needed. FDA required a post-marketing cardiovascular safety trial as a condition of lorcaserin's approval (a requirement for all weight management drugs since the withdrawal of sibutramine in 2010 due to cardiovascular harm). The CAMELLIA-TIMI 61 trial was conducted for this purpose, and it showed no difference in rates of major adverse cardiovascular events ("MACE+", a composite of "cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, heart failure, or any coronary revascularization") between lorcaserin and placebo. However secondary analysis of CAMELLIA-TIMI 61 by FDA showed a likely higher cancer risk in those taking lorcaserin. The trial was conducted in approximately 12,000 participants over five years and more patients taking lorcaserin were diagnosed with cancer compared to patients taking placebo. CAMELLIA-TIMI 61 was powered to detect differences in MACE, but was not adequately powered to detect differences in cancer rates over the five-year study period.
=== ATLAS and P-body === ATLAS and P-body (known as Blue and Orange to GLaDOS) are player characters in the co-op campaign of Portal 2. They are two robots that cannot speak and can only produce grunts, which are voiced by Dee Bradley Baker. They are equipped with their own portal guns which bears the colour of its user (blue and purple for ATLAS, yellow and red for P-body). Atlas and P-Body are described as masculine and feminine, respectively, as stated by Chet Faliszek in an interview. During the campaign, GLaDOS calls them Blue and Orange, respectively, and constantly tries to ruin their relationship by awarding one and ignoring the other. GLaDOS sends ATLAS and P-body into four areas to access data discs. Once done, they are blown up, as GLaDOS claims it is the only way they can be retrieved from these areas. Later, GLaDOS commands them to retrieve a certain "surprise" in an area. They go in search, only to find hundreds of thousands of other test subjects in suspended animation. After the co-op campaign is finished, GLaDOS quotes that they saved science. ATLAS and P-body begin to celebrate, only to be promptly blown up by GLaDOS. In the DLC campaign "Peer Review", ATLAS and P-body are reactivated by GLaDOS one week after the original co-op campaign, during which GLaDOS has already wiped out all of the found test subjects in her attempts to turn them into "killing machines". The two robots are sent to find a saboteur that has taken control of a prototype central core and is causing problems in the facility.
== Hfe knockout mice == It is possible to delete part or all of a gene of interest in mice (or other experimental animals), as a means of studying the function of the gene and its protein. Such mice are called "knockouts" with respect to the deleted gene. Hfe is the mouse equivalent of the human hemochromatosis gene HFE. The protein encoded by HFE is Hfe. Mice homozygous (two abnormal gene copies) for a targeted knockout of all six transcribed Hfe exons are designated Hfe−/−. Iron-related traits of Hfe−/− mice, including increased iron absorption and hepatic iron loading, are inherited in an autosomal recessive pattern. Thus, the Hfe−/− mouse model simulates important genetic and physiological abnormalities of HFE hemochromatosis. Other knockout mice were created to delete the second and third HFE exons (corresponding to α1 and α2 domains of Hfe). Mice homozygous for this deletion also had increased duodenal iron absorption, elevated plasma iron and transferrin saturation levels, and iron overload, mainly in hepatocytes. Mice have also been created that are homozygous for a missense mutation in Hfe (C282Y). These mice correspond to humans with hemochromatosis who are homozygous for HFE C282Y. These mice develop iron loading that is less severe than that of Hfe−/− mice.
This victory contributed to a general Allied breakthrough in the area, and by 19 April, the 6th Division's armour was moving towards Lombardy and Venetia as part of the Fifth Army's vanguard. American and Polish troops entered Bologna on 21 April. The South Africans and Rhodesians advanced north-west towards the Panaro river. The Special Service Battalion's Rhodesian squadron, moving forward alongside the Cape Town Highlanders, and the Rhodesians of Prince Alfred's Guard took part in numerous engagements with the retreating German rearguard, and suffered several fatalities. The 6th Division crossed the Po near Ostiglia on 25 April and, after resupplying for a week, began a speedy advance towards Venice, aiming to cut off the retreat of elements of the German Fourteenth Army. The South Africans and Rhodesians advanced through Nogara and Cerea, crossed the Adige early on 29 April, and then made for Treviso, 19 kilometres (12 mi) north of Venice. The retreating German forces were by this time in such disarray that, during its advance from the Po, the 11th South African Armoured Brigade took prisoners from eight German divisions. On 30 April, the 6th Division joined up with British and American forces south of Treviso, and cut off the Germans' last escape route from Italy. The German forces in Italy surrendered unconditionally on 2 May 1945, while the 6th Division was moving north-west; at the time of the announcement it was near Milan.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.